Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting, 25459-25460 [2013-10307]

Download as PDF Federal Register / Vol. 78, No. 84 / Wednesday, May 1, 2013 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Therapy (Omnibus). Date: June 27–28, 2013. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Caron A Lyman, Ph.D., Scientific Review Officer, National Cancer Institute, Division of Extramural Activities, Research Programs Review Branch, 9609 Medical Center Dr., Rm 7W412, Bethesda, MD 20892–975, 240–276–6348, lymanc@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 25, 2013. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–10199 Filed 4–30–13; 8:45 am] BILLING CODE 4140–01–P wreier-aviles on DSK5TPTVN1PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting 14:21 Apr 30, 2013 Jkt 229001 Name of Committee: National Cancer Institute Special Emphasis Panel; National Clinical Trial Network Groups. Date: July 16–17, 2013. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review Officer, National Cancer Institute, Division of Extramural Activities, Research Programs Review Branch, 9609 Medical Center Dr., Room 7W530, Bethesda, MD 20892–975, 240–276– 6442 ss537t@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 25, 2013. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–10200 Filed 4–30–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on May 23, 2013 from 1:00 to 3:30 p.m. at the Lister Hill Center Auditorium (Building 38A), National Library of Medicine, on the NIH Campus at 8600 Rockville Pike, Bethesda, MD 20894. The meeting is open to the public. The meeting will be held on May 23, 2013 from 1:00 to 3:30 p.m. Individuals wanting to present oral comments must notify the contact person at least 10 days before the meeting date. DATES: Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. VerDate Mar<15>2010 The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 25459 The meeting will be held at the Lister Hill Center Auditorium (Building 38A), National Library of Medicine, on the NIH Campus at 8600 Rockville Pike, Bethesda, MD 20894. ADDRESSES: For further information concerning this meeting, see the DMICC Web site, www.diabetescommittee.gov, or contact Dr. B. Tibor Roberts, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 31 Center Drive, Building 31A, Room 9A19, MSC 2560, Bethesda, MD 20892– 2560, telephone: 301–496–6623; FAX: 301–480–6741; email: dmicc@mail.nih.gov. FOR FURTHER INFORMATION CONTACT: The DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) comprising members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The May 23, 2013 DMICC meeting will focus on ‘‘Long-term Outcomes of Bariatric Surgery.’’ Any member of the public interested in presenting oral comments to the Committee should notify the contact person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives or organizations should submit a letter of intent, a brief description of the organization represented, and a written copy of their oral presentation in advance of the meeting. Only one representative of an organization will be allowed to present; oral comments and presentations will be limited to a maximum of 5 minutes. Printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, oral comments will be allowed on a first-come, first-serve basis. SUPPLEMENTARY INFORMATION: E:\FR\FM\01MYN1.SGM 01MYN1 25460 Federal Register / Vol. 78, No. 84 / Wednesday, May 1, 2013 / Notices Members of the public who would like to receive email notification about future DMICC meetings should register for the listserv available on the DMICC Web site, www.diabetescommittee.gov. Dated: April 25, 2013. B. Tibor Roberts, Executive Secretary, DMICC, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. MSC 7840, Bethesda, MD 20892, 301–435– 1256, harwoodj@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: April 25, 2013. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–10307 Filed 4–30–13; 8:45 am] [FR Doc. 2013–10198 Filed 4–30–13; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P Contact Person: Nadine Rogers, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892–9550, 301–402–2105, rogersn2@nida.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: April 25, 2013. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–10202 Filed 4–30–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES Center for Scientific Review; Notice of Closed Meetings National Institute on Drug Abuse; Notice of Closed Meetings National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. wreier-aviles on DSK5TPTVN1PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Name of Committee: Center for Scientific Review Special Emphasis Panel Member Conflict: Cardiovascular Epidemiology and Infectious Disease. Date: May 28, 2013. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Mary Ann Guadagno, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3170, MSC 7770, Bethesda, MD 20892, (301) 451– 8011, guadagma@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel Member Conflict: Eye Diseases #4. Date: May 28, 2013. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: James P Harwood, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5168, Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA I/START Small Grant Review. Date: June 19, 2013. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting). Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–402–6626, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Cohort Studies of HIV/AIDS and Substance Abuse (U01). Date: July 17, 2013. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). VerDate Mar<15>2010 14:21 Apr 30, 2013 Jkt 229001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Biomarker Study for Creatine Transporter Defect Disorders (Topic 002, SBIR Phase I, NCATS). Date: May 14, 2013. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Lyle Furr, Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892– 9550, (301) 435–1439, lf33c@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; SBIR Phase II Contract Review—Recovery Warrior: Behavioral Activation Video Game for Substance Abuse (Topic 141). Date: May 20, 2013. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate contract proposals. E:\FR\FM\01MYN1.SGM 01MYN1

Agencies

[Federal Register Volume 78, Number 84 (Wednesday, May 1, 2013)]
[Notices]
[Pages 25459-25460]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-10307]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Diabetes Mellitus Interagency Coordinating Committee 
Meeting

SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee 
(DMICC) will hold a meeting on May 23, 2013 from 1:00 to 3:30 p.m. at 
the Lister Hill Center Auditorium (Building 38A), National Library of 
Medicine, on the NIH Campus at 8600 Rockville Pike, Bethesda, MD 20894. 
The meeting is open to the public.

DATES: The meeting will be held on May 23, 2013 from 1:00 to 3:30 p.m. 
Individuals wanting to present oral comments must notify the contact 
person at least 10 days before the meeting date.

ADDRESSES: The meeting will be held at the Lister Hill Center 
Auditorium (Building 38A), National Library of Medicine, on the NIH 
Campus at 8600 Rockville Pike, Bethesda, MD 20894.

FOR FURTHER INFORMATION CONTACT: For further information concerning 
this meeting, see the DMICC Web site, www.diabetescommittee.gov, or 
contact Dr. B. Tibor Roberts, Executive Secretary of the Diabetes 
Mellitus Interagency Coordinating Committee, National Institute of 
Diabetes and Digestive and Kidney Diseases, 31 Center Drive, Building 
31A, Room 9A19, MSC 2560, Bethesda, MD 20892-2560, telephone: 301-496-
6623; FAX: 301-480-6741; email: dmicc@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The DMICC, chaired by the National Institute 
of Diabetes and Digestive and Kidney Diseases (NIDDK) comprising 
members of the Department of Health and Human Services and other 
federal agencies that support diabetes-related activities, facilitates 
cooperation, communication, and collaboration on diabetes among 
government entities. DMICC meetings, held several times a year, provide 
an opportunity for Committee members to learn about and discuss current 
and future diabetes programs in DMICC member organizations and to 
identify opportunities for collaboration. The May 23, 2013 DMICC 
meeting will focus on ``Long-term Outcomes of Bariatric Surgery.''
    Any member of the public interested in presenting oral comments to 
the Committee should notify the contact person listed on this notice at 
least 10 days in advance of the meeting. Interested individuals and 
representatives or organizations should submit a letter of intent, a 
brief description of the organization represented, and a written copy 
of their oral presentation in advance of the meeting. Only one 
representative of an organization will be allowed to present; oral 
comments and presentations will be limited to a maximum of 5 minutes. 
Printed and electronic copies are requested for the record. In 
addition, any interested person may file written comments with the 
Committee by forwarding their statement to the contact person listed on 
this notice. The statement should include the name, address, telephone 
number and when applicable, the business or professional affiliation of 
the interested person. Because of time constraints for the meeting, 
oral comments will be allowed on a first-come, first-serve basis.

[[Page 25460]]

    Members of the public who would like to receive email notification 
about future DMICC meetings should register for the listserv available 
on the DMICC Web site, www.diabetescommittee.gov.

    Dated: April 25, 2013.
B. Tibor Roberts,
Executive Secretary, DMICC, Office of Scientific Program and Policy 
Analysis, National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health.
[FR Doc. 2013-10307 Filed 4-30-13; 8:45 am]
BILLING CODE 4140-01-P